<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781078</url>
  </required_header>
  <id_info>
    <org_study_id>BSC-CDM00047737</org_study_id>
    <nct_id>NCT01781078</nct_id>
  </id_info>
  <brief_title>ImageReady(TM) MR Conditional Pacing System Clinical Study</brief_title>
  <acronym>SAMURAI</acronym>
  <official_title>ImageReady(TM) MR Conditional Pacing System Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the SAMURAI Clinical Study is to collect data to confirm the safety,
      performance and effectiveness of the ImageReady System for use in the Magnetic Resonance
      Imaging (MRI) environment when used in accordance with the Conditions of Use included in the
      Boston Scientific MRI Technical Guide
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Without MR Scan-related Complications</measure>
    <time_frame>MRI Visit + 1 Month</time_frame>
    <description>The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who undergo any portion of the MRI scan sequences. Safety will be confirmed by evaluating the MRI scan-related Complication-free rate (CFR) between the MR Scan and the MRI Visit + 1 Month Visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success Rate for Threshold Measurement at 1 Month Post-MRI Scan or Control Group Visit</measure>
    <time_frame>MRI + 1 Month Visit</time_frame>
    <description>The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to RF field-induced heating, which in turn may cause elevated pacing thresholds. Primary Effectiveness Endpoint 1 will evaluate any chronic effects from lead heating that will be seen through increased pacing threshold at the MRI Visit + 1 Month follow-up.
Subjects with an increase in pacing thresholds s 0.5V (at 0.5 ms) from pre-MR Scan/Control Group visit to MRI/Control visit + 1 Month follow-up were considered a success. A success rate was calculated for both the MRI and the Control Groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success Rate for Sensed Amplitude Measurement at 1 Month Post-MRI Scan or Control Group Visit</measure>
    <time_frame>MRI + 1 Month Visit</time_frame>
    <description>The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to Radiofrequency (RF) field-induced heating. Primary Effectiveness Endpoint 2 will evaluate any chronic effects from lead heating that will be seen through decreased sensed amplitude at the MRI Visit + 1 Month follow-up. Data were analyzed separately by chamber, Right Atrium (RA) and Right Ventricle (RV), for this endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Without ImageReady System-related Complications</measure>
    <time_frame>3 months post implant</time_frame>
    <description>Overall safety of the ImageReady System will be confirmed by evaluating system-related complications that occur from system implant through 3 months post implant for all subjects who underwent an implant procedure and and reached 91 days of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Bradycardia</condition>
  <condition>Sinus Node Dysfunction</condition>
  <arm_group>
    <arm_group_label>MRI Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment</description>
    <arm_group_label>MRI Group</arm_group_label>
    <other_name>MR Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ImageReady System implant</intervention_name>
    <description>Pacemaker and lead(s) implant</description>
    <arm_group_label>MRI Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Single chamber pacemaker implant</other_name>
    <other_name>Dual chamber pacemaker implant</other_name>
    <other_name>Pace/ Sense pacemaker lead implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have the ImageReady System as their initial (de novo) pacing system
             implant

          -  Subject has a Class I or II indication for implantation of a single or dual chamber
             pacemaker according to the ACC/AHA/HRS, or ESC guidelines, as appropriate per
             geography

          -  Subject is able and willing to undergo an MRI scan without intravenous sedation

          -  Subject is willing and capable of providing informed consent (which can include the
             use of a legally authorized representative (LAR) for documentation of informed
             consent) and participating in all testing/ visits associated with this clinical study
             at an approved clinical study center and at the intervals defined by this protocol

          -  Subject is age 18 or above, or of legal age to give informed consent specific to state
             and national law

        Exclusion Criteria:

          -  Subject has or has had any pacing or ICD system implants

          -  Subject has any MR Unsafe implants or devices with an unknown MR status, including MR
             Unsafe sternal wires, neurostimulators, biostimulator, metals or alloys, per labeling
             of each implant

          -  Subject has any MR Conditional implants or devices that impact the ability to conduct
             this protocol

          -  Subject needs or will need another MR scan within 14 weeks of system implant, other
             than that required by the SAMURAI Study

          -  Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)

          -  Subject has a mechanical tricuspid heart valve

          -  Subject is enrolled in any other concurrent study, with the exception of local
             mandatory governmental registries and observational studies/registries* that are not
             in conflict and do not affect the following:

               -  Schedule of procedures for the SAMURAI Study (i.e. should not cause additional or
                  missed visits);

               -  SAMURAI Study outcome (i.e. involve medications that could affect pacing
                  thresholds);

               -  Conduct of the SAMURAI Study per GCP/ ISO 14155:2011/ local regulations

          -  Subjects with documented permanent or persistent AF where the physician intends to
             implant a dual chamber pulse generator (single chamber VVIR pulse generators are
             acceptable)

          -  Subject is currently on the active heart transplant list

          -  Subject has documented life expectancy of less than 12 months

          -  Women of childbearing potential who are or might be pregnant at the time of study
             enrollment or ImageReady MR Conditional Pacing System implant (method of assessment
             upon physician's discretion)

          -  Subjects currently requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Berger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Hospital, Carnegie 530, 600 N. Wolfe St, Baltimore, MD 21287</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Heart Hospital</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Community Hospital</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oaks</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Duluth Clinic Regional Heart Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular Clinic</name>
      <address>
        <city>St Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research and Innovation Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity West Hospital</name>
      <address>
        <city>Steubenville</city>
        <state>Ohio</state>
        <zip>43952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Heart Hospital of South Dakota</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Mother Health Systems</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martha Jefferson Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital - Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Ste Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <zip>00000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre</name>
      <address>
        <city>Mistri Wing</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital, Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single chamber pacing</keyword>
  <keyword>Dual chamber pacing</keyword>
  <keyword>MRI</keyword>
  <keyword>MR scans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>363 patients were consented and enrolled in this study. 11 patients were withdrawn pre-implantation. 352 patients underwent the implantation procedure and 348 patients were successfully implanted. 1 patient died prior to randomization.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MRI Group</title>
          <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
ImageReady System implant: Pacemaker and lead(s) implant</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
ImageReady System implant: Pacemaker and lead(s) implant</description>
        </group>
        <group group_id="P3">
          <title>Patients Withdrawn Prior to Randomization</title>
          <description>Patients who consented to the study but were withdrawn prior to the randomization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229">Randomized post implantation</participants>
                <participants group_id="P2" count="118">Randomized post implantation</participants>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217">Patients having completed the MRI + 1 month (Primary endpoint assessment)</participants>
                <participants group_id="P2" count="113">Patients having completed the MRI + 1 month (Primary endpoint assessment)</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MRI Group</title>
          <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
ImageReady System implant: Pacemaker and lead(s) implant</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
ImageReady System implant: Pacemaker and lead(s) implant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="347"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="13.0"/>
                    <measurement group_id="B2" value="70.4" spread="11.9"/>
                    <measurement group_id="B3" value="69.4" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants Without MR Scan-related Complications</title>
        <description>The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who undergo any portion of the MRI scan sequences. Safety will be confirmed by evaluating the MRI scan-related Complication-free rate (CFR) between the MR Scan and the MRI Visit + 1 Month Visit.</description>
        <time_frame>MRI Visit + 1 Month</time_frame>
        <population>The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who underwent any portion of the MRI scan sequences and did not have a medically necessary scan performed prior to the MRI visit + 1 month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
ImageReady System implant: Pacemaker and lead(s) implant</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Without MR Scan-related Complications</title>
          <description>The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who undergo any portion of the MRI scan sequences. Safety will be confirmed by evaluating the MRI scan-related Complication-free rate (CFR) between the MR Scan and the MRI Visit + 1 Month Visit.</description>
          <population>The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who underwent any portion of the MRI scan sequences and did not have a medically necessary scan performed prior to the MRI visit + 1 month follow-up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Success Rate for Threshold Measurement at 1 Month Post-MRI Scan or Control Group Visit</title>
        <description>The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to RF field-induced heating, which in turn may cause elevated pacing thresholds. Primary Effectiveness Endpoint 1 will evaluate any chronic effects from lead heating that will be seen through increased pacing threshold at the MRI Visit + 1 Month follow-up.
Subjects with an increase in pacing thresholds s 0.5V (at 0.5 ms) from pre-MR Scan/Control Group visit to MRI/Control visit + 1 Month follow-up were considered a success. A success rate was calculated for both the MRI and the Control Groups.</description>
        <time_frame>MRI + 1 Month Visit</time_frame>
        <population>For the per-protocol analysis, a total of 96 Control Group subjects and 167 MRI Group subjects had paired threshold measurements and met the inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
ImageReady System implant: Pacemaker and lead(s) implant</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Those subjects randomized to the Control Group will not undergo study-specific MRI scan. All follow-up time requirements are the same for the two groups.
ImageReady System implant: Pacemaker and lead(s) implant</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate for Threshold Measurement at 1 Month Post-MRI Scan or Control Group Visit</title>
          <description>The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to RF field-induced heating, which in turn may cause elevated pacing thresholds. Primary Effectiveness Endpoint 1 will evaluate any chronic effects from lead heating that will be seen through increased pacing threshold at the MRI Visit + 1 Month follow-up.
Subjects with an increase in pacing thresholds s 0.5V (at 0.5 ms) from pre-MR Scan/Control Group visit to MRI/Control visit + 1 Month follow-up were considered a success. A success rate was calculated for both the MRI and the Control Groups.</description>
          <population>For the per-protocol analysis, a total of 96 Control Group subjects and 167 MRI Group subjects had paired threshold measurements and met the inclusion criteria.</population>
          <units>% of participants with success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The difference in the success rate between the 2 randomized groups was compared to 10% using a one-sided Farrington-Manning score test for non-inferiority at a significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Farrington-Manning score test</method>
            <param_type>difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Success Rate for Sensed Amplitude Measurement at 1 Month Post-MRI Scan or Control Group Visit</title>
        <description>The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to Radiofrequency (RF) field-induced heating. Primary Effectiveness Endpoint 2 will evaluate any chronic effects from lead heating that will be seen through decreased sensed amplitude at the MRI Visit + 1 Month follow-up. Data were analyzed separately by chamber, Right Atrium (RA) and Right Ventricle (RV), for this endpoint.</description>
        <time_frame>MRI + 1 Month Visit</time_frame>
        <population>Right Atrium: a total of 78 Control Group subjects and 135 MRI Group subjects had paired sensed amplitude measurements and met the inclusion criteria. Right Ventricle: a total of 91 Control Group subjects and 152 MRI Group subjects had paired sensed amplitude measurements and met the inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Those subjects randomized to the Control Group will not undergo study-specific MRI scan. All follow-up time requirements are the same for the two groups.
ImageReady System implant: Pacemaker and lead(s) implant</description>
          </group>
          <group group_id="O2">
            <title>MRI Group</title>
            <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
ImageReady System implant: Pacemaker and lead(s) implant</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate for Sensed Amplitude Measurement at 1 Month Post-MRI Scan or Control Group Visit</title>
          <description>The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to Radiofrequency (RF) field-induced heating. Primary Effectiveness Endpoint 2 will evaluate any chronic effects from lead heating that will be seen through decreased sensed amplitude at the MRI Visit + 1 Month follow-up. Data were analyzed separately by chamber, Right Atrium (RA) and Right Ventricle (RV), for this endpoint.</description>
          <population>Right Atrium: a total of 78 Control Group subjects and 135 MRI Group subjects had paired sensed amplitude measurements and met the inclusion criteria. Right Ventricle: a total of 91 Control Group subjects and 152 MRI Group subjects had paired sensed amplitude measurements and met the inclusion criteria.</population>
          <units>% of participants with success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Atrium (RA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ventricle (RV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The difference in the success rate between the 2 randomized groups was compared to 10% using a one-sided Farrington-Manning score test for non-inferiority at a significance level of 0.05.</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <method>Farrington-Manning score test</method>
            <param_type>difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The difference in the success rate between the 2 randomized groups was compared to 10% using a one-sided Farrington-Manning score test for non-inferiority at a significance level of 0.05.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Farrington-Manning score test</method>
            <param_type>difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Without ImageReady System-related Complications</title>
        <description>Overall safety of the ImageReady System will be confirmed by evaluating system-related complications that occur from system implant through 3 months post implant for all subjects who underwent an implant procedure and and reached 91 days of follow-up.</description>
        <time_frame>3 months post implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects Who Underwent an Implant Procedure</title>
            <description>All subjects who underwent an implant procedure and reached 91 days of follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Without ImageReady System-related Complications</title>
          <description>Overall safety of the ImageReady System will be confirmed by evaluating system-related complications that occur from system implant through 3 months post implant for all subjects who underwent an implant procedure and and reached 91 days of follow-up.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="91.9" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from enrollment through whole course of the study. Long-term follow-up is ongoing; subjects enrolled in SAMURAI study will be followed for 5 years post-implant.</time_frame>
      <desc>All Adverse Events are collected, as per ISO 14155: 2011 and/or 21 CFR Part 812.</desc>
      <group_list>
        <group group_id="E1">
          <title>MRI Group</title>
          <description>Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
ImageReady System implant: Pacemaker and lead(s) implant</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
ImageReady System implant: Pacemaker and lead(s) implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pulmonary edema - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Fatigue - Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertension - Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - Heart failure patient condition</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>3rd degree AV block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation (VF)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (VT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Torsades des pointes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation (AF)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other SVT (AVRT, AVNRT, EAT etc.)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Multiple symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism (PE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - Patient condition</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>AV Block Intermittent</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="229"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Patient condition</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Multi-system failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Adverse Reaction - Allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Early ERI - Random component failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Infection (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dislodgment - RA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - RA Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial perforation post-implant - RV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 ohms - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dislodgment - RV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="229"/>
                <counts group_id="E2" events="14" subjects_affected="5" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post-surgical infection (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Adverse reaction - General</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial perforation without tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial perforation with tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Adverse reaction - General</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pulmonary edema - Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypotension - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - Heart failure patient condition</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chronotropic incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia (VT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="229"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation (AF)</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="229"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other SVT (AVRT, AVNRT, EAT etc.)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions (PVC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="229"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Multiple symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Distal thromboemboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Unrelated to procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hematoma - Unrelated to procedure or device</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - Patient condition</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>AV Block Intermittent</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="229"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Patient condition</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="229"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="49" subjects_affected="36" subjects_at_risk="229"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Adverse Reaction - Allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="229"/>
                <counts group_id="E2" events="35" subjects_affected="22" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="229"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Oversensing - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Undersensing - RA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - PG system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Oversensing - RV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Rate response inappropriate</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Inappropriate AV delay</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pacemaker-mediated tachycardia (PMT)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Oversensing - RA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Undersensing - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - RA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dislodgment - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - RA Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Oversensing - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Undersensing - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Post-surgical pocket hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Post-surgical infection (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;=30 days post-implant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Puncture site hematoma - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial perforation without tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - PG system procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Protocol Testing - Adverse reaction - General</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Other - Protocol Testing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Beaudoint</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+32479904163</phone>
      <email>Caroline.Beaudoint@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

